View Post

PrimeVax Immuno-Oncology Receives IND Permission From FDA

In Clinical Trials by Barbara Jacoby

Source: PrimeVax Immuno-Oncology, Inc. From: prnewswire.com PrimeVax Immuno-Oncology, Inc. announced today that the company has successfully received their Investigational New Drug (IND) Application permission from the FDA to begin running their first human clinical trial. “Our goal is simple: treat melanoma patients who have exhausted their options,” states Tony Chen, PrimeVax’s CEO. “It has been a long road, but we …

View Post

Breast Cancer Drug Promising in Phase 3 Trial

In Clinical Trials by Barbara Jacoby

By: Steven Reinberg From: consumer.healthday.com For women with advanced breast cancer who carry the BRCA1 and BRCA2 gene mutations, an experimental drug could improve survival, a new study suggests. The BRCA mutations are linked with a greater risk for aggressive breast and ovarian cancer. The drug, talazoparib, works by blocking an enzyme called poly ADP ribose polymerase (PARP), thus preventing …

View Post

Novartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses

In Clinical Trials by Barbara Jacoby

Source: Novartis From: prnewswire.com – BYL719 plus fulvestrant meaningfully prolonged PFS vs fulvestrant alone in patients with PIK3CA mutated HR+/HER2- advanced breast cancer after progression on an aromatase inhibitor or after receiving up to one additional line of therapy1 – SOLAR-1 is the first Phase III breast cancer trial to demonstrate potential viability of using liquid biopsy to select patients …

View Post

Mayo researchers ID potential new treatment for one type of triple-negative breast cancer

In Clinical Trials by Barbara Jacoby

Source: Mayo Clinic From: eurekalert.org Mayo Clinic researchers have identified the drug estradiol as a potential new treatment for a subset of women with triple-negative breast cancer. Their findings are published in the Proceedings of the National Academy of Sciences of the United States of America. “Triple-negative breast cancer is a form of breast cancer that lacks expression of estrogen …

View Post

Breast cancer drug in first human clinical trial

In Clinical Trials by Barbara Jacoby

By: Jacqueline Carey, University of Illinois at Chicago From: medicalxpress.com A University of Illinois at Chicago-developed breast cancer drug that has the potential to help women whose cancer has stopped responding to hormone therapy recently entered its first human clinical trial. Breast cancer affects one in eight women in the United States, and while there are many types of breast …

View Post

Inovio Announces Initiation of “MD Anderson’s HPV-Related Cancers Moon Shot” Phase 2 Trial in New HPV Indications

In Clinical Trials by Barbara Jacoby

Source: Inovio Pharmaceuticals, Inc. From: globenewswire.com Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today the dosing of the first patient in a Phase 2 combination trial to evaluate MedImmune’s MEDI0457 (formerly called INO-3112 which MedImmune in-licensed from Inovio) in combination with durvalumab targeting a broad array of cancers associated with the human papilloma virus (HPV). This open-label trial funded by MedImmune, the …

View Post

Proposed NRG-BN006 Phase 2/3 trial to begin enrollment in 2019

In Clinical Trials by Barbara Jacoby

Tocagen Inc. (TOCA), a late clinical-stage, cancer-selective gene therapy company and NRG Oncology, a member of the National Cancer Institute’s (NCI) National Clinical Trial Network (NCTN), today announced that the NCI Cancer Therapy and Evaluation Program (CTEP) Brain Malignancies Steering Committee has approved a concept to develop a clinical trial utilizing the investigational therapeutic regimen Toca 511 (vocimagene amiretrorepvec) & …

View Post

New dual-action cancer-killing virus

In Clinical Trials by Barbara Jacoby

From: eurekalert.org Scientists have equipped a virus that kills carcinoma cells with a protein so it can also target and kill adjacent cells that are tricked into shielding the cancer from the immune system. It is the first time that cancer-associated fibroblasts within solid tumours – healthy cells that are tricked into protecting the cancer from the immune system and …

View Post

Targeting Innovation in Small Cell Lung Cancer

In Clinical Trials by Barbara Jacoby

By: Heather Stringer From: curetoday.com After consulting multiple doctors about her ongoing cough and congestion, LeeAnn Devore asked one of her physicians if she might have lung cancer. “He said the symptoms weren’t right,” says Devore, 66, of Magnolia, Texas. Three X-rays in five months confirmed that she had pneumonia in her right lung, yet she wasn’t responding to traditional …

View Post

First-in-Human Trial Launched for Super-Enhancer Inhibitor GZ17-6.02

In Clinical Trials by Barbara Jacoby

SOURCE: Translational Drug Development From: apnews.com Genzada Pharmaceuticals USA Inc., a subsidiary of Ionics Life Sciences Limited (Genzada), announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for a Phase 1 human clinical trial of the company’s flagship molecule GZ17-6.02 (6.02) for patients with advanced solid organ tumors or lymphoma. “We …